News: Express Scripts Holding Co (ESRX.O)

ESRX.O on Nasdaq

65.90USD
28 Jul 2014
Price Change (% chg)

$-0.45 (-0.68%)
Prev Close
$66.35
Open
$66.75
Day's High
$66.99
Day's Low
$65.78
Volume
10,016,552
Avg. Vol
5,416,550
52-wk High
$79.37
52-wk Low
$59.20

Search Stocks
Select another date:

Mon, Jun 2 2014

Fitch Rates Express Scripts' Proposed Bond Offering 'BBB'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, June 02 (Fitch) Fitch Ratings has assigned a 'BBB' rating to the proposed senior unsecured bond issuance by Express Scripts Holding Company (NYSE:ESRX). Proceeds from the issuance are expected to be used for the redemption of ESRX's $900 million and $1.25 billion of unsecured bonds due November 2014 and November 2016, respectively, and for general corporate purposes (including some share repurchase). Fitch currently rates

DIARY-U.S. MEETINGS/WEEK AHEAD

THOMSON REUTERS, May 06,2014 - Corporate Meetings for US companies for Week ahead. S&P 500 Earnings - Weekly S&P 500 Earnings - Day Ahead Non S&P 500 - Weekly Non S&P 500 - Day Ahead ConferenceCall/Webcast - Weekly ConferenceCall/Webcast - Day S&P 500 Earnings - Monthly Meetings - Day Ahead Economic Indicators Dividends Daily earnings hits & misses Federal Rese

Novo cuts sales forecast after U.S. contract losses

COPENHAGEN - Denmark's Novo Nordisk A/S , the world's top maker of insulin, has lowered its 2014 sales outlook, hurt by the loss of two U.S. contracts and competition from copycat versions of its diabetes drug Prandin, it said on Thursday.

CORRECTED-UPDATE 2-Novo cuts sales forecast after U.S. contract losses

(Corrects MAY 1 story to show Q1 sales growth 7 pct in local currencies, Novo Nordics' most valuable company)

DIARY-U.S. MEETINGS/WEEK AHEAD

THOMSON REUTERS, May 01,2014 - Corporate Meetings for US companies for Week ahead. S&P 500 Earnings - Weekly S&P 500 Earnings - Day Ahead Non S&P 500 - Weekly Non S&P 500 - Day Ahead ConferenceCall/Webcast - Weekly ConferenceCall/Webcast - Day S&P 500 Earnings - Monthly Meetings - Day Ahead Economic Indicators Dividends Daily earnings hits & misses Federal Rese

Novo cuts sales forecast after U.S. contract losses

COPENHAGEN - Denmark's Novo Nordisk A/S , the world's top maker of insulin, has lowered its 2014 sales outlook, hurt by the loss of two U.S. contracts and competition from copycat versions of its diabetes drug Prandin, it said on Thursday.

UPDATE 2-Novo cuts sales forecast after U.S. contract losses

* Sales growth below double-digit for first time in 48 qtrs

Express Scripts says significance of subpoenas still unclear

April 30 - Pharmacy benefit manager Express Scripts Holding Co on Wednesday said it is too soon to know the significance of three government subpoenas it has received since February, which asked about the company's business dealings with U.S. and European drugmakers.

BRIEF-Express Scripts weighs options regarding costly Sovaldi hepatitis C drug

April 30 - Express Scripts Holding Co : * Says considering a number of initiatives to benefit clients and patients

Express Scripts first-quarter profit falls, lowers 2014 forecast

- Pharmacy benefit manager Express Scripts Holding Co on Tuesday posted a lower-than-expected first-quarter profit and decreased its earnings forecast for full-year 2014, saying adjusted prescription volume would be less than it had anticipated.

Select another date:
Search Stocks